Trade

with

Emergent BioSolutions Inc
(NYSE: EBS)
AdChoices
21.60
+0.29
+1.36%
After Hours :
-
-
-

Open

21.58

Previous Close

21.31

Volume (Avg)

149 (206.29k)

Day's Range

21.25-21.99

52Wk Range

18.28-28.48

Market Cap.

809.51M

Dividend Rate ( Yield )

-

Beta

1.08

Shares Outstanding

37.48M

P/E Ratio (EPS)

59.52 (0.36)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 312.74M

    • Net Income

    • 31.14M

    • Market Cap.

    • 809.51M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 3.84

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.08

    • Forward P/E

    • -

    • Price/Sales

    • 2.29

    • Price/Book Value

    • 1.66

    • Price/Cash flow

    • 15.75

      • EBITDA

      • 62.32M

      • Return on Capital %

      • 1.94

      • Return on Equity %

      • 2.88

      • Return on Assets %

      • 1.94

      • Book Value/Share

      • 13.02

      • Shares Outstanding

      • 37.48M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • 20.00

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • 1.24

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 33.80

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • 32.40

          • 17.04

          • Net Income

            Q/Q (last year)

          • -52.00

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 11.86

          • 63.43

          • Net Income

            5-Year Annual Average

          • 8.50

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 73.54

            • 82.75

            • Pre-Tax Margin

            • 5.98

            • 39.38

            • Net Profit Margin

            • 3.84

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 82.40

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • 16.00

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • 11.60

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.51

              • 0.76

              • Current Ratio

              • 4.52

              • 2.92

              • Quick Ratio

              • 3.44

              • 2.35

              • Interest Coverage

              • 5.01

              • 38.02

              • Leverage Ratio

              • 1.72

              • 2.21

              • Book Value/Share

              • 13.02

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 58.82

                • 243.90

                • P/E Ratio 5-Year High

                • 78.43

                • 634.30

                • P/E Ratio 5-Year Low

                • 34.04

                • 124.82

                • Price/Sales Ratio

                • 2.26

                • 9.29

                • Price/Book Value

                • 1.64

                • 8.39

                • Price/Cash Flow Ratio

                • 15.75

                • 49.75

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 2.88

                    (9.80)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • 1.94

                    (7.20)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • 2.71

                    (8.20)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • 9.98k

                  • 117.08k

                  • Inventory Turnover

                  • 2.20

                  • 1.48

                  • Asset Turnover

                  • 0.50

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  42.80M
                  Operating Margin
                  13.69
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  15.75
                  Ownership

                  Institutional Ownership

                  83.70%

                  Top 10 Institutions

                  39.79%

                  Mutual Fund Ownership

                  40.79%

                  Float

                  78.10%

                  5% / Insider Ownership

                  7.06%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Dreyfus Opportunistic Small Cap Fund

                  •  

                    1,475,416

                  • 0.00

                  • 3.94

                  • iShares Core S&P Small-Cap (AU)

                  •  

                    591,987

                  • 0.57

                  • 1.58

                  • SPDR® S&P Biotech ETF

                  •  

                    576,607

                  • -9.84

                  • 1.54

                  • Vanguard Small Cap Index

                  •  

                    521,566

                  • -0.03

                  • 1.39

                  • Vanguard Total Stock Mkt Idx

                  •  

                    500,390

                  • 0.00

                  • 1.34

                  • Glenmede Small Cap Equity Portfolio

                  •  

                    487,547

                  • 34.86

                  • 1.30

                  • Loomis Sayles Small Cap Growth Fund

                  •  

                    448,541

                  • -3.58

                  • 1.20

                  • iShares Russell 2000 (AU)

                  •  

                    442,320

                  • -1.80

                  • 1.18

                  • PowerShares Dynamic Biotech&Genome Port

                  •  

                    441,771

                  • 0.00

                  • 1.19

                  • Vanguard Small Cap Growth Index Fund

                  •  

                    352,922

                  • -1.68

                  • 0.94

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Boston Co Asset Management LLC

                  •  

                    2,891,944

                  • +0.35%

                  • 7.72

                  • Broadfin Capital, LLC

                  •  

                    2,080,519

                  • +15.24%

                  • 5.55

                  • Vanguard Group, Inc.

                  •  

                    2,016,586

                  • +1.92%

                  • 5.38

                  • Dreyfus Corporation

                  •  

                    1,572,959

                  • 0.00%

                  • 4.20

                  • BlackRock Fund Advisors

                  •  

                    1,499,600

                  • -2.35%

                  • 4.00

                  • Dimensional Fund Advisors, Inc.

                  •  

                    1,476,073

                  • +15.46%

                  • 3.94

                  • State Street Corp

                  •  

                    1,219,071

                  • -2.91%

                  • 3.25

                  • Loomis Sayles & Company L.P.

                  •  

                    910,115

                  • +6.26%

                  • 2.43

                  • Numeric Investors LLC

                  •  

                    636,759

                  • +2.89%

                  • 1.70

                  • Renaissance Technologies Corp

                  •  

                    607,511

                  • -20.37%

                  • 1.62

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Slow Growth

                  Style

                  Small Growth

                  Emergent BioSolutions Inc., was incorporated as BioPort Corporation under the laws of Michigan in May 1998 and subsequently reorganized as a Delaware corporation in June 2004. The Company is a biopharmaceutical company, which is focu...moresed on the development, manufacture and commercialization of vaccine and immune-related therapeutic that assist the body’s immune system to prevent or treat disease. It develops vaccines and therapeutics for use against biological agents that are potential weapons of bioterrorism and biowarfare and infectious diseases that have resulted in significant unmet or underserved public health needs. The Company manufactures and markets BioThrax(r), also referred to as anthrax vaccine adsorbed, the only vaccine approved by the U.S. Food and Drug Administration, or FDA, for the p...morerevention of anthrax infection. BioThrax is approved for pre-exposure prevention of anthrax infection by all routes of exposure, including inhalation. The Company operates in two business segments, biodefense and biosciences. Its biodefense segment focuses on vaccines and therapeutics for use against biological agents that are potential weapons of bioterrorism or biowarfare. Its product candidates in this segment are focused on two specific biological agents: anthrax and botulinum. Within its anthrax product portfolio, the Company manufactures and markets BioThrax(r) (Anthrax Vaccine Adsorbed), the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection. In addition to BioThrax, the Company is developing a recombinant protective antigen anthrax, or rPA, vaccine an advanced BioThrax vaccine, an anthrax immune globulin therapeutic and a recombinant anthrax monoclonal antibody therapeutic. Within its botulinum product portfolio, it is developing a recombinant botulinum vaccine. The Company’s Biosciences division is a specialty pharmaceutical business focused on therapeutics and vaccines in hematology/oncology, transplantation and infectious disease. The Company’s products and any product or product candidate that it acquires or successfully develop and commercialize is likely to compete with currently marketed products, such as vaccines, antibody therapies, antibiotics and other product candidates that are in development for the same indications. Specifically, the competition for its products and product candidates includes BioThrax, RSDL, BAT, AIGIV, VIGIV and PreviThrax and NuThrax. Accordingly, it is subject to federal, state, local and foreign laws and regulations governing the use, manufacture, distribution, storage, handling, disposal and recordkeeping of these materials.lessless

                  Key People

                  Daniel J. Abdun-Nabi

                  CEO/Director/President

                  Fuad El-Hibri

                  Chairman of the Board/Director

                  Mr. Robert G. Kramer,Sr

                  CFO/Chief Accounting Officer/Executive VP, Divisional/Treasurer

                  Anatolio B. Cruz,III

                  Executive VP/General Counsel/Secretary

                  Barry A. Labinger

                  Executive VP/President, Divisional

                  • Emergent BioSolutions Inc

                  • 2273 Research Boulevard

                  • Rockville, MD 20850

                  • USA.Map

                  • Phone: +1 301 795-1800

                  • Fax: +1 301 795-1899

                  • emergentbiosolutions.com

                  Incorporated

                  1998

                  Employees

                  1,353

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: